Keros Therapeutics (KROS) Change in Accured Expenses (2019 - 2025)
Keros Therapeutics posted quarterly Change in Accured Expenses of -$4.4 million for Q4 2025, down 241.03% year-on-year from $3.1 million in Q4 2024, and up 7.61% on a QoQ basis from -$4.8 million in Q3 2025.
Keros Therapeutics (KROS) has 7 years of Change in Accured Expenses data on file, last reported at -$4.4 million in Q4 2025.
- For the quarter ending Q4 2025, Change in Accured Expenses fell 241.03% year-over-year to -$4.4 million; the trailing twelve-month figure through Dec 2025 stood at -$10.1 million (down 443.19% YoY), and the FY2025 full-year result was -$10.1 million, down 443.19% from the prior year.
- Change in Accured Expenses for Q4 2025 stood at -$4.4 million, up from -$4.8 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $8.7 million in Q3 2024 and bottomed at -$5.4 million in Q1 2024.
- The 5-year median for Change in Accured Expenses is $317500.0 (2022), against an average of $302600.0.
- The widest annual swing landed in 2022, when Change in Accured Expenses soared 4494.85%; it then tumbled 647.65% in 2023.
- A 5-year view of Change in Accured Expenses shows it stood at -$97000.0 in 2021, then jumped by 4494.85% to $4.3 million in 2022, then soared by 35.75% to $5.8 million in 2023, then tumbled by 122.45% to -$1.3 million in 2024, then sank by 241.03% to -$4.4 million in 2025.
- The last three Change in Accured Expenses figures came in at -$4.4 million (Q4 2025), -$4.8 million (Q3 2025), and $2.7 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 931,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 70.50 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -176.03 Mn |
| 10 | Keros Therapeutics | 403.85 Mn | 116.45 Mn | - | -4.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -4.43 Mn |
| Dec 31, 2025 | -4.43 Mn |
| Sep 30, 2025 | -4.80 Mn |
| Sep 30, 2025 | -4.80 Mn |
| Jun 30, 2025 | 2.67 Mn |
| Jun 30, 2025 | 2.67 Mn |
| Mar 31, 2025 | -3.58 Mn |
| Mar 31, 2025 | -3.58 Mn |
| Dec 31, 2024 | -1.30 Mn |
| Dec 31, 2024 | -1.30 Mn |
| Sep 30, 2024 | 8.71 Mn |
| Sep 30, 2024 | 8.71 Mn |
| Jun 30, 2024 | 900,000.00 |
| Jun 30, 2024 | 900,000.00 |
| Mar 31, 2024 | -5.35 Mn |
| Mar 31, 2024 | -5.35 Mn |
| Dec 31, 2023 | 5.79 Mn |
| Dec 31, 2023 | 5.79 Mn |
| Sep 30, 2023 | 274,000.00 |
| Sep 30, 2023 | 274,000.00 |
| Jun 30, 2023 | 1.17 Mn |
| Jun 30, 2023 | 1.17 Mn |
| Mar 31, 2023 | -1.98 Mn |
| Mar 31, 2023 | -1.98 Mn |
| Dec 31, 2022 | 4.26 Mn |
| Dec 31, 2022 | 4.26 Mn |
| Sep 30, 2022 | 1.28 Mn |
| Sep 30, 2022 | 1.28 Mn |
| Jun 30, 2022 | -583,000.00 |
| Jun 30, 2022 | -583,000.00 |
| Mar 31, 2022 | 361,000.00 |
| Mar 31, 2022 | 361,000.00 |
| Dec 31, 2021 | -97,000.00 |
| Dec 31, 2021 | -97,000.00 |
| Sep 30, 2021 | 1.65 Mn |
| Sep 30, 2021 | 1.65 Mn |
| Jun 30, 2021 | 204,000.00 |
| Jun 30, 2021 | 204,000.00 |
| Mar 31, 2021 | 894,000.00 |
| Mar 31, 2021 | 894,000.00 |
| Dec 31, 2020 | -85,000.00 |
| Dec 31, 2020 | -85,000.00 |
| Sep 30, 2020 | 1.66 Mn |
| Sep 30, 2020 | 1.66 Mn |
| Jun 30, 2020 | -2.25 Mn |
| Jun 30, 2020 | -2.25 Mn |
| Mar 31, 2020 | 3.27 Mn |
| Mar 31, 2020 | 3.27 Mn |
| Dec 31, 2019 | 26,000.00 |
| Dec 31, 2019 | 26,000.00 |
| Sep 30, 2019 | 910,000.00 |
| Sep 30, 2019 | 910,000.00 |
| Jun 30, 2019 | 78,000.00 |
| Jun 30, 2019 | 78,000.00 |
| Mar 31, 2019 | 177,000.00 |
| Mar 31, 2019 | 177,000.00 |